

UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF MASSACHUSETTS

BIONTECH SE, BIONTECH  
MANUFACTURING GMBH,  
AND PFIZER INC.,

Case No. 1:22-cv-11202-NMG

Plaintiffs,

v.

CUREVAC AG,

Defendant.

**PLAINTIFFS' ASSENTED-TO MOTION TO EXTEND THE DEADLINE TO FILE A  
RESPONSE TO DEFENDANT'S MOTION TO DISMISS FOR LACK OF PERSONAL  
JURISDICTION OR TO TRANSFER PURSUANT TO 28 U.S.C. § 1631**

Plaintiffs BioNTech SE and BioNTech Manufacturing GmbH (“BioNTech Manufacturing,” and with BioNTech SE collectively, “BioNTech”) and Pfizer Inc. (“Pfizer”) (collectively, “Plaintiffs”), hereby move, on an assented-to basis, for an extension of time until December 5, 2022 for the Plaintiffs to respond to the defendant’s motion to dismiss for lack of personal jurisdiction or to transfer pursuant to 28 U.S.C. § 1631 (the “Motion to Dismiss”).

As grounds for this motion, the Plaintiffs state as follows:

1. The Plaintiffs commenced this action by filing their Complaint on July 25, 2022.
2. Pursuant to a Waiver of Service sent on July 29, 2022, the defendant’s response was due by October 27, 2022.
3. The defendant filed the Motion to Dismiss on October 27, 2022.
4. The parties have conferred regarding the timing of the Plaintiffs’ response to the Motion to Dismiss. The defendant assents to an extension of the deadline for the Plaintiffs to respond to the Motion to Dismiss until December 5, 2022.

5. No extension of time has previously been sought or granted with respect to this deadline, and this extension is sought to accommodate the schedules of counsel, including lead counsel for BioNTech being away for trial in another matter.

WHEREFORE, the Plaintiffs respectfully move this Court for the entry of an Order extending the time for the Plaintiffs to file a response to the Motion to Dismiss until December 5, 2022.

PLAINTIFFS,

By their Counsel,

*/s/ Jeffrey S. Robbins*

---

Jeffrey S. Robbins, BBO #421910  
Jeffrey.Robbins@saul.com  
Joseph D. Lipchitz, BBO #632637  
Joseph.Lipchitz@saul.com  
Gregory M. Boucher, BBO #665212  
Gregory.Boucher@saul.com  
SAUL EWING ARNSTEIN & LEHR LLP  
131 Dartmouth Street, Suite 501  
Boston, MA 02116  
Tel: (617) 723-3300

Admitted Pro Hac Vice:

Bruce M. Wexler  
Eric W. Dittmann  
Young J. Park  
Mi Zhou  
Michael F. Werno  
Alexander C. Plushanski  
PAUL HASTINGS LLP  
200 Park Avenue  
New York, NY 10166  
(212) 318-6000

*Attorneys for Plaintiffs BioNTech*

Admitted Pro Hac Vice:

Thomas J. Meloro  
Michael W. Johnson  
Heather M. Schneider  
Jennifer Liu  
Brian W. Frino  
WILLKIE FARR & GALLAGHER LLP  
787 Seventh Avenue  
New York, NY 10019  
(212) 728-8000

Sara Tonnies Horton  
WILLKIE FARR & GALLAGHER LLP  
300 North LaSalle Drive  
Chicago, IL 60654  
(312) 728-9040

*Attorneys for Plaintiff Pfizer Inc.*

Assented-to:

/s/ Michael R. Gottfried  
Michael R. Gottfried (BBO No. 542156)  
DUANE MORRIS LLP  
100 High Street, Suite 2400  
Boston, MA 02110  
Tel: 857.488.4200  
Fax: 857.488.4201  
mrgottfried@duanemorris.com

Mark H. Izraelewicz (pro hac vice)  
MARSHALL, GERSTEIN & BORUN LLP  
233 S. Wacker Drive  
6300 Willis Tower  
Chicago, Illinois 60606  
mizraelewicz@marshallip.com  
Tel: 857.488.4200  
Fax: 857.488.4201

*Attorneys for Defendant CureVac AG*

Dated: November 3, 2022

**CERTIFICATE OF SERVICE**

I, Jeffrey S. Robbins, hereby certify that this document filed through the ECF system will be sent electronically to the registered participants as identified on the Notice of Electronic Filing (NEF) and paper copies will be sent to those indicated as non-registered participants on November 3, 2022.

/s/ Jeffrey S. Robbins  
Jeffrey S. Robbins